Neurogene (NASDAQ:NGNE) Now Covered by Analysts at Lifesci Capital

Lifesci Capital began coverage on shares of Neurogene (NASDAQ:NGNE) in a research note issued to investors on Monday,Benzinga reports. The firm issued an outperform rating and a $50.00 price target on the stock.

Several other brokerages also recently commented on NGNE. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a research report on Thursday. Wall Street Zen cut Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $70.00 price objective on shares of Neurogene in a research report on Tuesday, January 13th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $44.00.

Neurogene Stock Up 4.4%

NASDAQ NGNE opened at $19.12 on Monday. Neurogene has a 52 week low of $6.88 and a 52 week high of $37.27. The company has a market capitalization of $296.17 million, a P/E ratio of -4.65 and a beta of 1.60. The stock’s 50-day moving average price is $19.72 and its 200-day moving average price is $22.02.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.27. Research analysts anticipate that Neurogene will post -4.27 EPS for the current year.

Institutional Trading of Neurogene

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets grew its holdings in Neurogene by 89.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after purchasing an additional 978 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Neurogene by 24.7% during the third quarter. PNC Financial Services Group Inc. now owns 5,055 shares of the company’s stock valued at $88,000 after buying an additional 1,000 shares during the last quarter. ADAR1 Capital Management LLC grew its stake in shares of Neurogene by 3.4% during the third quarter. ADAR1 Capital Management LLC now owns 30,633 shares of the company’s stock valued at $531,000 after buying an additional 1,008 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Neurogene by 17.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after buying an additional 1,059 shares during the period. Finally, Raiffeisen Bank International AG raised its holdings in shares of Neurogene by 13.3% in the third quarter. Raiffeisen Bank International AG now owns 34,000 shares of the company’s stock worth $602,000 after buying an additional 4,000 shares during the period. Hedge funds and other institutional investors own 52.37% of the company’s stock.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.